Methods and compositions for ATP-sensitive K.sup.+ channel inhibition for lowering intraocular pressure
AssigneeVide Pharmaceuticals
InventorsNino Sorgente, Charles Bakhit
Life of this patent
Estimating the term…
Abstract
ATP-sensitive K.sup.+ channel modulating compounds are incorporated into ophthalmically acceptable carriers for administration to the eye in order to affect intraocular pressure. Such formulations including compounds which inhibit the channel are particularly suitable for treating glaucoma and other disorders related to elevated intraocular pressure. Such formulation which potentiates the channel are particularly suitable for treating hypotonia and other depressed intraocular pressure conditions.
Claims14
A method for reducing intraocular pressure in an eye of a patient, said method comprising administering to the eye a sulfonylurea compound having ATP-sensitive K+ channel inhibitory activity present in an ophthalmically acceptable carrier in an amount effective to lower said intraocular pressure.
A method for reducing intraocular pressure in an eye of a patient, said method comprising administering to the eye a sulfonylurea compound selected for the group consisting of glybenclamide, glipizide, tolbutamide, tolazamide, chlorpropamide, and therapeutically equivalent salts or derivatives thereof present in an ophthalmically acceptable carrier in an amount effective to lower said intraocular pressure.
Dependencies are inferred from the claim text.